Genomic Diagnostics

Site

GD QLD – Healius Pathology Pty Ltd

Accreditation No.

19619

Site No.

25049

Date of Accreditation

01 Jun 2017

Address

Ground Floor, 11 Riverview Place
Murarrie, QLD 4172
Australia

genomicdiagnostics.com.au

Contact

Ms Jodie Fitness P: +61 (07) 31214593

Availability

Services available to external clients

Supervision

B (Branch)

Genomic Diagnostics address map

Scope of Accreditation

Print scopes
GD QLD – Healius Pathology Pty Ltd

ISO 15189 (2022)

  • This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.

Human Pathology

Service Product Determinant
Cytogenetics - Detection of defined, balanced and/or unbalanced chromosomal abnormalities by in situ hybridisation techniques Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Other body fluids; Other tissues - Malignant; Other tissues - Non-malignant; Paraffin embedded tissue; Smears; Tissues Chromosomal rearrangement; Cytogenetic analysis and reporting; Pathogenic copy number changes
Cytogenetics - Karyotype detection of balanced and/or unbalanced chromosome abnormalities Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Other tissues - Malignant; Other tissues - Non-malignant Constitutional genetic abnormalities; Pathogenic copy number changes
Cytogenetics - Molecular karyotype (SNP microarray) detection of unbalanced chromosome abnormalities Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Other tissues - Malignant; Other tissues - Non-malignant Cytogenetic analysis and reporting; Pathogenic copy number changes
Immunopathology - Single HLA antigen typing Blood HLA-B27
Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes Blood β-Thalassaemia
Apolipoprotein E genotyping; Factor V Leiden; Haemochromatosis; Methylenetetrahydrofolate reductase (MTHFR); Prothrombin variant
Y chromosome microdeletion
α-Thalassaemia
Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genesPrimary bioinformatics only – wet lab and reporting done by GX lab (19619 22717). Blood Fragile X
Molecular genetics - DNA extraction Amniotic fluid; Blood; Bone marrow; Cerebrospinal fluid (CSF); Chorionic villus tissue; Cultured cells; Extracted DNA; Fibroblast cell pellets; Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Frozen tissue; Muscle; Pleural fluid; Products of conception (POC); Skin biopsy; Tissue biopsy; Tissues; Trephine DNA storage for future analyses; Purified PCR product; Quantification of DNA; Viable DNA; Viable DNA for sequencing; Viable DNA for sequencing and other molecular assays
Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes Blood; Bone marrow JAK2 mutation analysis
Quantitative calculation of p210 positive BCR::ABL1 transcripts
Nucleophosmin 1 (NPM1) mutation
FLT3-ITD (internal tandem duplication) mutation; FLT3-TKD (tyrosine kinase domain) mutation
Qualitative calculation of p190 positive BCR::ABL1 transcripts
B and T-cell gene rearrangement studies
Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted panels for non-inherited (somatic) DNA/RNA changes Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Tissues Solid tumours
Molecular genetics - RNA extraction Blood; Bone marrow Viable RNA for molecular diagnostics

The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.

Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.